Form 4: MDxHealth CCO John Bellano Receives Stock Option Grant

MDxHealth Chief Commercial Officer John Bellano was granted 333,000 stock options with an exercise price of $0.76.

Summary

• John Bellano, Chief Commercial Officer of MDxHealth SA, received a grant of 333,000 stock options on June 1, 2026.
• The grant is split into two tranches: 116,000 performance-based options and 217,000 time-based options.
• All options carry an exercise price of $0.76 per share and expire on May 28, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Aligns executive compensation with long-term shareholder value through equity-based incentives.
• Includes performance-based vesting criteria, incentivizing the achievement of specific company goals.

Negatives

• Results in potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Vesting of performance-based options is contingent upon meeting specific company criteria, which may not be achieved.
• Market price of MDxHealth shares may fluctuate, impacting the ultimate value of the granted options.

Future Outlook

The options vest over time and upon the achievement of performance criteria, indicating management's focus on long-term operational and financial targets.

Management Comments

• The options are subject to vesting schedules: one tranche based on performance criteria and one tranche vesting in three equal annual installments.

Industry Context

StockSavvy.ai notes that equity grants for C-suite executives in the biotech and diagnostics sector are standard practice to ensure leadership retention and alignment with corporate milestones.

Comparison to Industry Standards

• The use of a mix of time-based and performance-based vesting is consistent with standard corporate governance practices for executive compensation in the healthcare sector.
• The 10-year term for options is standard for equity incentive plans in publicly traded companies.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of 217,000 time-based options in three equal annual installments starting June 1, 2027.
• Evaluation of performance criteria by the Board of Directors for the 116,000 performance-based options.

Key Dates

Keywords

MDxHealth, MDXH, Form 4, Insider Trading, Stock Options, Executive Compensation